About Flexion Therapeutics
Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company's other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: FLXN
- Previous Close: $19.27
- 50 Day Moving Average: $19.09
- 200 Day Moving Average: $18.62
- 52-Week Range: $27,527,000.00 - $7.56
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.72
- P/E Growth: 0.00
- Market Cap: $530.45M
- Outstanding Shares: 27,527,000
- Beta: 1.31
- Return on Equity: -51.43%
- Return on Assets: -42.30%
Companies Related to Flexion Therapeutics:
- Debt-to-Equity Ratio: 0.17%
- Current Ratio: 13.01%
- Quick Ratio: 13.01%
What is Flexion Therapeutics' stock symbol?
Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."
Where is Flexion Therapeutics' stock going? Where will Flexion Therapeutics' stock price be in 2017?
8 brokerages have issued 12 month price targets for Flexion Therapeutics' stock. Their forecasts range from $0.02 to $38.00. On average, they anticipate Flexion Therapeutics' share price to reach $29.57 in the next year.
When will Flexion Therapeutics announce their earnings?
Flexion Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.
What are analysts saying about Flexion Therapeutics stock?
Here are some recent quotes from research analysts about Flexion Therapeutics stock:
According to Zacks Investment Research, "Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company's product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts. " (2/21/2017)
- BMO Capital Markets analysts commented, "While the company did not receive a priority review, we had not been expecting that, and had always assumed a standard 10-month review. It was good to see the FDA accept the NDA with no major issues, and we remain confident in the approval of Zilretta at the PDUFA. Reiterate our Outperform; FLXN remains a top pick." (2/7/2017)
Cantor Fitzgerald analysts commented, "Timing For Review: With the NDA filed in December 2016, the FDA has 60 days to decide whether to confer a Priority Review on Zilretta. Though we do see merit in prioritization, given the Fast Track designation, clean safety profile and need for longer duration, non-opioid pain options, recent FDA decisions make us question whether a reformulation will be deemed appropriate for a condensed review process." (1/17/2017)
Who owns Flexion Therapeutics stock?
Flexion Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Novo A S (5.08%), Kingdon Capital Management L.L.C. (5.01%), State Street Corp (1.42%), Alyeska Investment Group L.P. (0.91%), Allianz Asset Management AG (0.59%) and Wall Street Associates (0.31%). Company insiders that own Flexion Therapeutics stock include A/S Novo, C Ann Merrifield, Frederick W Driscoll, Michael D Clayman, Neil Bodick and Samuel D Colella.
Who sold Flexion Therapeutics stock? Who is selling Flexion Therapeutics stock?
Flexion Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Allianz Asset Management AG, Wall Street Associates and GRT Capital Partners L.L.C..
Who bought Flexion Therapeutics stock? Who is buying Flexion Therapeutics stock?
Flexion Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Kingdon Capital Management L.L.C., Novo A S, Alyeska Investment Group L.P., State Street Corp, Guggenheim Capital LLC, Russell Investments Group Ltd., Raymond James Financial Services Advisors Inc. and Keybank National Association OH. Company insiders that have bought Flexion Therapeutics stock in the last two years include C Ann Merrifield, Frederick W Driscoll, Michael D Clayman, Neil Bodick and Samuel D Colella.
How do I buy Flexion Therapeutics stock?
Shares of Flexion Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Flexion Therapeutics stock cost?
One share of Flexion Therapeutics stock can currently be purchased for approximately $19.27.